NCI-2023-06119

Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer CP-MVC-101-01

This is a Phase 1/2 research study is evaluating a novel treatment called TAK-186 (also known as MVC-101) in patients with unresectable locally advanced or metastatic cancer. TAK-186 is a type of treatment known as a conditional bispecific redirected activation (COBRA) protein. It is designed to target both the epidermal growth factor receptor (EGFR), which is often overexpressed in many cancers, and CD3, a protein found on T cells that helps activate an immune response against cancer cells. The study includes patients with unresectable locally advanced or metastatic cancer, meaning their cancer cannot be removed by surgery and has spread to nearby tissues or to other parts of the body. The primary objective of this trial, designated as CP-MVC-101-01, is to assess the safety profile of TAK-186/MVC-101 and gather preliminary data on its effectiveness in treating advanced cancers. If successful, the study may pave the way for further development and potential approval of TAK-186 as a new treatment option for these challenging types of cancer.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04844073

Clinical Trial Site: Columbia

To see all available clinical trials click here.